Cell surface phenotype, cytokines, and antibody gene expression in immortalized human B cell lines

1990 ◽  
Vol 1 (3) ◽  
pp. 145-153 ◽  
Author(s):  
K. James ◽  
J. Gardner ◽  
G. Skibinski ◽  
M. McCann ◽  
R. Thorpe ◽  
...  
Blood ◽  
1992 ◽  
Vol 80 (3) ◽  
pp. 724-732 ◽  
Author(s):  
Y Pang ◽  
Y Norihisa ◽  
D Benjamin ◽  
RR Kantor ◽  
HA Young

Human interferon-gamma (IFN-gamma) is an important immunomodulatory protein produced predominantly by T cells and large granular lymphocytes (LGLs). Whereas large amounts of data have been accumulated regarding IFN gamma gene expression in these two cell types, little information about IFN gamma expression in other cell types exists. In this study, we have analyzed the production of IFN gamma by the Epstein- Barr virus (EBV)-positive B-cell line, JLP(c), derived from a patient with Burkitt's lymphoma, and another human B-cell line, PA682BM-1, which was derived from an acquired immunodeficiency syndrome patient. Southern blot analysis indicates the presence of an Ig heavy chain gene rearrangement, but no rearrangement of the T-cell receptor beta chain gene or IFN gamma gene in these B-cell lines. Both cell lines were found to express surface IgD and other B-cell surface markers, thus confirming their B-cell lineage. Analysis for surface Ig, cytoplasmic Ig, and secreted Ig indicates that the two cell lines are in relatively early stages of the B-cell differentiation pathway. We now report that PA682BM-1 can be triggered by the protein kinase C (PKC) activators, phorbol 12-myristate 13-acetate (PMA) and (-)Indolactam-v, to secrete IFN gamma, whereas JLP(c) cells spontaneously produce low levels of IFN gamma that can be enhanced by PKC activators and interleukin-2 (IL-2). After activation of the cell lines with IL-2, (-)Indolactam-v, and PMA, increases in cytoplasmic messenger RNAs (mRNAs) of IFN gamma and the IL- 2 receptor chains were also observed. The induction of IFN gamma mRNA and protein by IL-2 was completely blocked by a monoclonal antibody to IL-2 receptor p75 (beta chain), but not by the monoclonal antibody to p55 (alpha chain). Analysis of IFN gamma genomic DNA indicates that the gene is not amplified, but that hypomethylation in the 5′ noncoding region of the IFN gamma gene has occurred in the B-cell line from the Burkitt's lymphoma patient that spontaneously produces IFN gamma. This finding suggests that the methylation state of the promoter region may play an important role in the control of IFN gamma gene expression in B cells.


Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 1997-1997
Author(s):  
Ru Feng ◽  
Fangying Zheng ◽  
J. Jessica Yu ◽  
B. Hilda Ye

Abstract Abstract 1997 Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma, characterized by heterogeneity in its clinical, immunophenotypic, and genetic features. Gene-expression profiling studies have distinguished 3 molecular subtypes of DLBCL known as germinal center B-cell-like (GCB) DLBCL, activated B-cell-like (ABC) DLBCL, and type III. When treated with CHOP or other CHOP-like regimens, patients with GCB-DLBCL have a better survival than those with ABC-DLBCL. CD44 is a widely expressed type I transmembrane glycoprotein and functions as the major hyaluronan receptor on many cell types. In a number of solid tumors, CD44 plays an important role in tumor invasion and metastasis. In DLBCL, CD44 is expressed at significantly higher levels in ABC-DLBCL compared to GCB-DLBCL. In addition, co-expression of CD44 splice variants with the hyaluronan receptor predicts a very poor prognosis in patients treated with standard CHOP therapy. Despite these published observations, there is only limited understanding regarding the role of CD44 in the cellular behavior and gene expression control of DLBCL cells. To address this issue, we first profiled cell surface expression of CD44 in 4 DLBCL cell lines by flow cytometry. Two GCB-DLBCL lines (OCI-Ly1 and OCI-Ly8) and two ABC-DLBCL lines (SUDHL-2 and OCI-Ly3) were analyzed. The percentage of CD44 positive cells in SUDHL-2, OCI-Ly3, OCI-Ly1 and OCI-Ly8 cells was 74.57±5.03%, 44.01±3.70%, 0.12±0.05%, 0.14±0.03%, respectively. Next, we evaluated the invasion ability of 3 cell lines by the Matrigel Transwell assay. For the SUDHL-2, OCI-Ly1, and OCI-Ly8 cells, the percentage of invaded cells in 4 hours was 72.7±11.7%, 20.0±8.6%, and 30.3±7.5%, respectively. The ABC-DLBCL line, SUDHL-2, was significantly more invasive compared with OCI-Ly1 and OCI-Ly8 (P<0.01). No significant difference was found between the two GCB-DLBCL lines, OCI-Ly1 and OCI-Ly8 (P=0.238). To study the role of CD44 in cell invasion, we down-regulated the expression of CD44 with retrovirus -mediated short hairpin RNA (shRNA) interference. After stable integration of retroviral vectors, stable subclones were obtained by puromycin selection. Effect of the knock-down on CD44 expression in ABC-DLBCL cells (SUDHL-2) was confirmed by flow cytometry. For SUDHL-2, CD44 level in shRNA expressing cells was reduced to 51.72±0.49% (one week), 38.31±1.24% (two weeks), and 16.29±11.17% (three weeks), respectively. In conclusion, we have confirmed the differential expression pattern of CD44 in DLBCL subtypes using cell line models. Our data also indicates that the level of CD44 expression positively correlates with cell invasion capability, such that ABC-DLBCL cells are more invasive compared with GCB-DLBCL cells. This difference may potentially contribute to the unfavorable treatment outcome of ABC-DLBCL. Lastly, we demonstrate that shRNA-mediated knock-down can stably and substantially reduce the endogenous CD44 expression on the cell surface. This experimental system is expected to provide a useful tool for further investigation of CD44 as a regulator of cellular behavior and chemotherapy response in DLBCL. Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
1992 ◽  
Vol 80 (3) ◽  
pp. 724-732 ◽  
Author(s):  
Y Pang ◽  
Y Norihisa ◽  
D Benjamin ◽  
RR Kantor ◽  
HA Young

Abstract Human interferon-gamma (IFN-gamma) is an important immunomodulatory protein produced predominantly by T cells and large granular lymphocytes (LGLs). Whereas large amounts of data have been accumulated regarding IFN gamma gene expression in these two cell types, little information about IFN gamma expression in other cell types exists. In this study, we have analyzed the production of IFN gamma by the Epstein- Barr virus (EBV)-positive B-cell line, JLP(c), derived from a patient with Burkitt's lymphoma, and another human B-cell line, PA682BM-1, which was derived from an acquired immunodeficiency syndrome patient. Southern blot analysis indicates the presence of an Ig heavy chain gene rearrangement, but no rearrangement of the T-cell receptor beta chain gene or IFN gamma gene in these B-cell lines. Both cell lines were found to express surface IgD and other B-cell surface markers, thus confirming their B-cell lineage. Analysis for surface Ig, cytoplasmic Ig, and secreted Ig indicates that the two cell lines are in relatively early stages of the B-cell differentiation pathway. We now report that PA682BM-1 can be triggered by the protein kinase C (PKC) activators, phorbol 12-myristate 13-acetate (PMA) and (-)Indolactam-v, to secrete IFN gamma, whereas JLP(c) cells spontaneously produce low levels of IFN gamma that can be enhanced by PKC activators and interleukin-2 (IL-2). After activation of the cell lines with IL-2, (-)Indolactam-v, and PMA, increases in cytoplasmic messenger RNAs (mRNAs) of IFN gamma and the IL- 2 receptor chains were also observed. The induction of IFN gamma mRNA and protein by IL-2 was completely blocked by a monoclonal antibody to IL-2 receptor p75 (beta chain), but not by the monoclonal antibody to p55 (alpha chain). Analysis of IFN gamma genomic DNA indicates that the gene is not amplified, but that hypomethylation in the 5′ noncoding region of the IFN gamma gene has occurred in the B-cell line from the Burkitt's lymphoma patient that spontaneously produces IFN gamma. This finding suggests that the methylation state of the promoter region may play an important role in the control of IFN gamma gene expression in B cells.


1997 ◽  
Vol 10 (4) ◽  
pp. 183-195 ◽  
Author(s):  
ROSEMARY ROCHFORD ◽  
MARTIN J. CANNON ◽  
REBECCA E. SABBE ◽  
KALYANI ADUSUMILLI ◽  
GASTON PICCHIO ◽  
...  

1989 ◽  
Vol 1 (4) ◽  
pp. 362-366 ◽  
Author(s):  
Ton Logtenberg ◽  
Mieke E. M. Schutte ◽  
Giorgio Inghirami ◽  
Jeffrey E. Berman ◽  
Frits H. J. Gmelig-Meyling ◽  
...  

1982 ◽  
Vol 156 (1) ◽  
pp. 104-111 ◽  
Author(s):  
JP Johnson ◽  
T Meo ◽  
G Reithmuller ◽  
DJ Schendel ◽  
R Wank

A murine monoclonal antibody directed against a human B cell surface antigen with the characteristics of HLA-DR is described. The antigen detected is tightly linked to HLA and is correlated with the alloantigen HLA-Dw/DR3. Reactivity with a fraction of Dw/DRw6 cells is also observed. The determinant recognized by this antibody has been shown to be present on the smaller molecular weight β subunit of the HLA-DR antigen.


Sign in / Sign up

Export Citation Format

Share Document